IRLAB obtains strengthened patent protection for Phase II candidate pirepemat

September 2, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) today announced that the company has been granted a new patent on the manufacturing process for the drug candidate pirepemat by the US Patent Office. Pirepemat is one of IRLAB’s clinical drug candidates and under development in Phase IIb for the treatment of impaired balance and falls in Parkinson’s disease.

Read More >

IRLAB publishes interim report for April 1 – June 30, 2021

August 25, 2021 Regulatory

IRLAB (Nasdaq Stockholm: IRLAB A) today announced that the company’s interim report for the second quarter 2021 (April 1 – June 30, 2021) has been published.

Read More >

IRLAB invites to a conference call in connection with the signed licensing deal with Ipsen for drug candidate mesdopetam

July 16, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) announced late yesterday that a licensing agreement has been entered with the global biopharmaceutical company Ipsen for the drug candidate mesdopetam. In connection with this, IRLAB invites investors, analysts and media to a conference call on July 16, 2021, at 10:00 CET.

Read More >


IR contact

Viktor Siewertz, CFO
+46(0)72 710 70 70